An Open-Label Extension of SELECT

March 9, 2015

Lori J. Wirth, MD, discusses an open-label extension of the phase III SELECT trial, which looked at lenvatinib versus placebo for differentiated thyroid cancer.

Clinical Pearls

Lori J. Wirth, MD, medical director, Center for Head and Neck Cancers, Massachusetts General Hospital, assistant professor, Harvard Medical School, discusses an open-label extension of the phase III SELECT trial, which looked at lenvatinib versus placebo for the treatment of patients with relapsed/refractory differentiated thyroid cancer.

In SELECT, median PFS was 18.3 months with lenvatinib and 3.6 months with placebo.
In the open-label extension, PFS was slightly lower (12.4 months). The overall response rate was 54.9%.
The best time to initiate treatment in RAI-refractory patients is unknown.

<<<